On August 5, 2026, Beijing Zhiyuan Technology Co., Ltd. secured nearly 200 million yuan in its A2 round of financing. This round was led by Sansure Biotech and its industrial fund, with continued participation from CAS Star, and additional investments from Zhangjiang Venture Capital and others. The funds will be used for the continuous generation of high-value innovative IP, global asset deployment, and the upgrade of the AI4S platform driven by a life-world model.